Coimbra S, et al. – The potential of brodalumab was explored in the treatment of moderate–to–severe psoriasis. The findings obtained from Phase I and Phase II clinical trials were suggestive of brodalumab being a favorable safety and tolerability profile, with strong clinical activity. This, in turn, indicated that it was a potential instrument for use in the treatment of moderate–to–severe psoriasis.